Sema4|GeneDx to Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study.  Learn more >>

Comprehensive Common Cancer Panel

New York
Approved


Genes

APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCC, FANCM, FH, FLCN, HOXB13, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51C, RAD51D, RECQL, SCG5 (GREM1), SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL

Conditions

  • Colorectal Cancer
  • Endometrial Cancer
  • Familial Adenomatous Polyposis (FAP)
  • Ovarian Cancer
  • Pancreatic Cancer
  • Attenuated Familial Adenomatous Polyposis (AFAP)
  • Breast Cancer

Clinical Utility

  • Cancer at a young age, such as breast, colon, or renal cancer
  • Multiple cancers in one person, either of the same origin (such as two separate colon cancers) or of different origins (such as breast cancer and ovarian cancer)
  • Diagnosis of certain rare cancers, such as ovarian or male breast cancer
  • Multiple relatives diagnosed with the same or related cancers on the same side of the family and spanning multiple generations

Lab Method

  • Deletion/Duplication Analysis
  • Next-Gen Sequencing

Test Code

B275

CPT Codes*

81433x1, 81432x1 (HBOC diagnosis); 81435x1, 81436x1 (non-HBOC diagnosis)

ABN Required

No

Turnaround Time**

2 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs | Fibroblasts (separate charge for cell culture may apply)

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.